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a b s t r a c t
INTRODUCTION: Gastrointestinal stromal tumors (GIST) are uncommon, potentially malignant tumors,
that arise in the wall of the gastrointestinal tract. Up to 50% can develop metastasis, mainly in the liver,
but the occurrence of synchronous primary liver tumors is a rare event in these patients.
PRESENTATION OF CASE: The authors report a case of the association of gastric GIST and hepatocellular
carcinoma (HCC) in a non-cirrhotic liver in a 76 year-old patient.
DISCUSSION:Theappearanceof anhepatic lesion in aGISTpatient doesnotnecessarily imply its secondary
nature.
CONCLUSION: In diagnosed GIST patients, all efforts should be pursued to characterize synchronous
hepatic lesions, in order to plan a correct and tailored treatment of the patients.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Gastrointestinal stromal tumors (GIST) are uncommon, poten-
tially malignant tumors that arise in the wall of the gastrointestinal
tract. These tumors account for 1% of all gastrointestinal neoplasms
[1] and they are the most frequent mesenchymal tumors in that
location [2–3]. They can occur in any portion of digestive tract but
they are mainly localized in the stomach (40–65%) and small intes-
tine (25–40%). Its occurrence has a unimodal distribution with a
mean at-onset age varying between 59 and 79 years [1–6], with a
male increased relative risk [4]. GIST typically exhibits immuno-
histochemical positivity for vimentin in almost all cases, for CD117
(c-Kit) in 95% and for CD34 in 60–70% (80% in gastric location)
[7]. The occurrence of simultaneous tumors in patients with GIST
has been reported in 13–43% of patients [8–10] and up to 50% can
develop metastasis, mainly in the liver [5]. GIST can occur simulta-
neously with chronic lymphocytic leukemia, lymphoma, renal cell
carcinoma or gastric cancer, but the association with hepatocellu-
lar carcinoma (HCC) is extremely rare [10]. The incidence of HCC
is increasing. This tumor typically arises in an underlying cirrhotic
liver, with well known risk factors including alcoholic abuse, hep-
atitis B and C chronic infections, non-alcoholic steatohepatitis and
other causes of cirrhosis. Up to 25% of tumors, however, arise in
non-cirrhotic livers [11] and despite their frequent large size when
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diagnosed, potentially curative treatments can be offered with a
better outcome than tumors arising in cirrhotic liver. [12]
Herein, we report a challenging diagnosis and decision mak-
ing case of a patient admitted to our medical institution with the
unusual coexistence of a gastric GIST and HCC developing in a non-
cirrhotic liver.
2. Presentation of case
A 76 year-old caucasian male was admitted in our emergency
department with an upper gastrointestinal bleeding episode asso-
ciated with mild upper abdominal pain and non quantiﬁed weight
loss. Three years previously, the patient had been submitted to a
distal gastrectomywith a Billroth II reconstruction at another insti-
tution in an attempt to remove a gastric GIST; no tumor, however,
was identiﬁed in the surgical specimen, and the patient deliber-
ately refused any further treatment or follow-up at that institution.
Apart from minor depression, no other signiﬁcant medical history
was noticed. He was medicated with dulosepin 75mg i.d. and pan-
toprazole 40mg i.d. He was negative for hepatitis virus B and C
infection markers.
The physical exam only identiﬁed skin pallor. Blood tests
showed haemoglobin of 5.5 g/dL and no other relevant changes.
The patient was transfused with 3 red blood cell units. An upper
endoscopy was performed and a polypoid bulging segment with
a central bleeding ulceration below the cardia was identiﬁed. The
bleeding was successfully controlled by endoscopic clipping and
adrenalin injection.
http://dx.doi.org/10.1016/j.ijscr.2015.05.020
2210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. CT-imaging showing the hepatic and gastric masses.
Fig. 2. Intra-operative view: (a) performed gastrostomy with gastric lesion; (b)
hepatic lesion.
A CT-scan showed a 78×86mm tumor in the stomach rem-
nant and a 34×28mm nodular lesion in the left liver lobe, with
associated biliary dilatation (Fig. 1).
Echoendoscopic guided biopsies of the gastric and the hepatic
lesions were performed and the pathological results were compat-
ible with GIST (CD117+; vimentin+) in the gastric lesion and HCC
(HepPar1+; CK7; HSP-70+; Glutaminsynthetase+ [13–14]) in the
liver nodule.
At laparotomy, a posterior gastric wall infra-cardiac pedicled
lesion with the same size described in CT-scan and a segment III
lesion were observed. An anterior gastrotomy was performed in
Fig. 3. (a) Biopsy specimens of the GIST with immunoexpression of C-kit (40X); (b)
hepatocellular carcinoma in a non-cirrhotic liver (H&E; 40X).
order to enable an atypical gastrectomy of the posterior wall lesion
area (Fig. 2a), preserving the previous Billroth II gastrointestinal
continuity, and a left liver ultrasound guided lobectomy was fol-
lowed (Fig. 2b).
Histologically the gastric tumor was compatible with GIST
(Fig. 3a). It was 85mm long, with a mitotic index of 4/50HPF [15].
The hepatic tumor was catalogued as HCC and the underlying liver
showed no evidence of cirrhosis (Fig. 3b). The immunohistochem-
ical patterns were similar to those on the previous biopsies. The
postoperative period was uneventfully and the patient was dis-
charged on the 7th post-operative day.
The patientwasmonitored in regular follow-up until 30months
after surgery. No signs of recurrence were found.
3. Discussion
A high (13–43%) prevalence of synchronous malignant tumors
has been reported in GIST patients [8–9], with no literature con-
sensus as to the role (if any) of genetic and environmental factors
[8]. Synchronous primary liver tumors are not common in these
patients [6] and the association of GIST and HCC remains an excep-
tional event, with very few cases published to the best of our
knowledge: one case of perivascular epithelioid cell tumor of the
liver [16] and 2 cases of HCC (one c-Kit positive and other c-Kit
negative) [17,18] have been reported in association with GIST.
In this context, even considering the relatively high potential
to metastasize to the liver, the appearance of an hepatic lesion in
GIST patients does not warrant its secondary nature. Therefore, if
feasible, a biopsy is of utmost importance in planning the correct
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treatment of these patients, especially, as in the present case, when
both lesions are considered resectable.
In this case, the diagnostic and staging work-up established the
two independent diagnoses and led to the R0 resection of both
tumors and to a potentially better prognosis than if the liver lesion
had been considered a metastasis from the gastric GIST. In that sit-
uation the patient would have been driven to a life-long treatment
with a TK inhibitor [19].
4. Conclusion
Despite few reports has shown GIST and HCC association,
considering the multiple different treatment perspectives, in diag-
nosed GIST patients all efforts should be pursued to characterize
synchronous hepatic lesions with independent biopsies, in order
to plan a correct and tailored treatment of the patients.
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